224 related articles for article (PubMed ID: 18160251)
21. Chemotherapy of prostate cancer: present and future.
Trump D; Lau YK
Curr Urol Rep; 2003 Jun; 4(3):229-32. PubMed ID: 12756087
[TBL] [Abstract][Full Text] [Related]
22. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K
Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy in the treatment of prostate cancer--is there a role?
Arianayagam M; Chang J; Rashid P
Aust Fam Physician; 2007 Sep; 36(9):737-9. PubMed ID: 17885709
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel in the management of prostate cancer: current standard of care and future directions.
De Dosso S; Berthold DR
Expert Opin Pharmacother; 2008 Aug; 9(11):1969-79. PubMed ID: 18627334
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
Logothetis CJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):63-72. PubMed ID: 12108899
[TBL] [Abstract][Full Text] [Related]
29. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Lheureux S; Joly F
Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
[TBL] [Abstract][Full Text] [Related]
30. New treatment options for castrate-resistant prostate cancer: a urology perspective.
Gomella LG; Gelpi F; Kelly WK
Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
[TBL] [Abstract][Full Text] [Related]
31. [Hormone-refractory prostate cancer].
Alexandre I; Rixe O
Ann Urol (Paris); 2007 Apr; 41(2):47-55. PubMed ID: 17486912
[TBL] [Abstract][Full Text] [Related]
32. Treatment options in hormone-refractory metastatic prostate carcinoma.
Fusi A; Procopio G; Della Torre S; Ricotta R; Bianchini G; Salvioni R; Ferrari L; Martinetti A; Savelli G; Villa S; Bajetta E
Tumori; 2004; 90(6):535-46. PubMed ID: 15762353
[TBL] [Abstract][Full Text] [Related]
33. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
34. [Docetaxel and prostate cancer].
Ferrero JM
Bull Cancer; 2004 Feb; 91(2):172-7. PubMed ID: 15047457
[TBL] [Abstract][Full Text] [Related]
35. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Berry WR
Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
[TBL] [Abstract][Full Text] [Related]
36. Role of chemotherapy in prostate cancer.
Nader R; El Amm J; Aragon-Ching JB
Asian J Androl; 2018; 20(3):221-229. PubMed ID: 29063869
[TBL] [Abstract][Full Text] [Related]
37. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
[TBL] [Abstract][Full Text] [Related]
38. [Strategy in advanced castration-resistant prostate cancer].
Gross-Goupil M; Roca S; Pasticier G; Ravaud A
Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.
Sinibaldi VJ
Clin Interv Aging; 2007; 2(4):555-60. PubMed ID: 18225455
[TBL] [Abstract][Full Text] [Related]
40. The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer.
Gupta K; Elkon J; El-Bahesh E; Aragon-Ching JB
Anticancer Agents Med Chem; 2016; 16(9):1166-71. PubMed ID: 24359499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]